Cartalax 20mg (Bioregulator)

Cartalax

Peptide bioregulator for joint and cartilage support (non-medicinal research/supplement product)

Synthetic tripeptide joint and cartilage bioregulator

Cartalax does not appear as an authorised active substance or product in the UK MHRA licensed medicines database.
No European Medicines Agency (EMA) European Public Assessment Report (EPAR) exists for a medicinal product named Cartalax, and there is no centrally authorised EU marketing authorisation listing Cartalax as an active substance.
Research Chemical and peptide vendors explicitly label Cartalax 20mg vials as for research use only and not for human or veterinary use, indicating that these vials are not approved medicinal products.
Cartalax capsule and lingual bioregulator products in European markets are clearly labelled as not a medicinal product and positioned under food/supplement Style regulatory frameworks rather than medicines regulation.
Vendors outside the EU include disclaimers that Cartalax has not been evaluated by regulators such as the US Food and Drug Administration and is not intended to diagnose, treat, cure or prevent any disease.
No CE or UKCA medical device certification is publicly indicated for Cartalax 20mg; it is not registered as a medical device in major device databases.
No MHRA Product Licence (PL) number, EMA authorisation number or other major Regulator approval identifiers have been identified for Cartalax at the time of verification.

Cartalax does not appear as an authorised active substance or product in the UK MHRA licensed medicines database.
No European Medicines Agency (EMA) European Public Assessment Report (EPAR) exists for a medicinal product named Cartalax, and there is no centrally authorised EU marketing authorisation listing Cartalax as an active substance.
Research Chemical and peptide vendors explicitly label Cartalax 20mg vials as for research use only and not for human or veterinary use, indicating that these vials are not approved medicinal products.
Cartalax capsule and lingual bioregulator products in European markets are clearly labelled as not a medicinal product and positioned under food/supplement Style regulatory frameworks rather than medicines regulation.
Vendors outside the EU include disclaimers that Cartalax has not been evaluated by regulators such as the US Food and Drug Administration and is not intended to diagnose, treat, cure or prevent any disease.
No CE or UKCA medical device certification is publicly indicated for Cartalax 20mg; it is not registered as a medical device in major device databases.
No MHRA Product Licence (PL) number, EMA authorisation number or other major Regulator approval identifiers have been identified for Cartalax at the time of verification.

Synthetic tripeptide joint and cartilage bioregulator

Description

Cartalax 20mg (Bioregulator) is a peptide-based bioregulator product marketed by Dermal Skin LTD as an advanced peptide for joint and cartilage support. The product page describes Cartalax 20mg as a cutting-edge bioregulator formulated with bioactive peptides to support joint and cartilage health, promote cellular regeneration, enhance mobility, and aid in the recovery of connective tissues. Cartalax itself (also known as Ala-Glu-Asp, AED, or T-31) is a synthetic tripeptide developed in Russia and discussed in the scientific literature as a research-stage anti-ageing bioregulator with potential relevance to cartilage and connective tissue. Reference databases describe Cartalax as the tripeptide alanyl-glutamyl-aspartic acid with molecular formula C12H19N3O8 and molecular weight 333.29 g/mol. Research and bioregulator vendors classify Cartalax as a cartilage and bone tissue bioregulator studied for its role in supporting chondrocyte activity, collagen synthesis, extracellular matrix composition, and musculoskeletal integrity in experimental models. It is sold internationally as a high-purity lyophilised peptide (for research use only) and in some markets as non-medicinal capsule or lingual bioregulator products for joint and musculoskeletal support, typically labelled as not a medicinal product.

Bnefits

Supports joint and cartilage health – Dermal Skin LTD describes Cartalax 20mg as a bioregulator designed to support joint and cartilage health and assist recovery of connective tissues.
Promotes mobility and flexibility – the product is marketed as helping to enhance mobility and flexibility, making it suitable for individuals with joint discomfort, athletes and ageing adults.
Helps maintain connective tissue health – Cartalax is presented by multiple vendors as a cartilage and bone tissue bioregulator studied for its role in supporting chondrocyte activity, collagen synthesis and skeletal/connective-tissue integrity in research settings.
Anti-ageing bioregulator profile – scientific summaries and peptide guides classify Cartalax as an anti-ageing bioregulator that may reduce cellular senescence and support restoration of function in ageing cells in vitro and in animal models.
Tissue-targeted peptide – research-vendor descriptions note that Cartalax (Ala-Glu-Asp) is based on sequences associated with cartilage-related proteins and is intended to target biological pathways relevant to cartilage and musculoskeletal tissues.
High-purity lyophilised peptide – research suppliers of Cartalax 20mg typically specify high purity (≥95–98% or higher) and supply the peptide as a lyophilised powder in vials for controlled laboratory or formulation use.
Part of the Khavinson peptide/bioregulator family – Cartalax is listed among short regulatory peptides studied for modulation of gene expression and tissue-specific regulation, particularly in the context of joint and cartilage-related tissues.
Positioned for long-term musculoskeletal wellness – Dermal Skin LTD markets Cartalax 20mg towards individuals seeking to maintain long-term musculoskeletal wellness and joint comfort, in combination with broader wellness and lifestyle strategies.

Indications

Commercial/wellness indication: marketed by Dermal Skin LTD as a bioregulator designed to support joint and cartilage health, promote mobility and flexibility, and aid in recovery of connective tissues in individuals with joint discomfort or high activity levels.
Target users per Dermal Skin LTD: athletes, active individuals, ageing adults and those seeking to maintain long-term musculoskeletal wellness.
Bioregulator indication (capsule/lingual products from other manufacturers): recommended as an adjuvant in the complex support of degenerative-dystrophic musculoskeletal conditions (e.g. arthrosis, arthritis, rheumatism, osteochondrosis, osteoporosis and gout) alongside standard care, according to non-medicinal bioregulator product literature.
Research indication: described in scientific and vendor summaries as a research-stage peptide bioregulator studied for its potential to influence cartilage and connective-tissue cell functions, including chondrocyte activity, extracellular matrix composition, inflammatory signalling and markers of cellular ageing in vitro and in animal models.
Cartalax is not authorised by major medicines regulators (such as MHRA, EMA or FDA) as a medicinal product for any indication; capsule and lingual Cartalax products in the EU and other markets are explicitly labelled as not a medicinal product, and peptide-vial suppliers state that their products are for research use only.

Composition

Active peptide: Cartalax (also known as Ala-Glu-Asp, AED, T-31), a synthetic tripeptide with amino acid sequence alanyl-glutamyl-aspartic acid.
Chemical name (IUPAC) and identifiers: the tripeptide is described in reference sources as alanyl-glutamyl-aspartic acid with IUPAC name corresponding to a tripeptide of alanine, glutamic acid and aspartic acid, commonly associated with the Cartalax entry.
Molecular formula: C12H19N3O8.
Molecular weight: approximately 333.29 g/mol, as listed in chemical and research compound databases for alanyl-glutamyl-aspartic acid/Cartalax.
Synonyms: Cartalax; Ala-Glu-Asp; alanyl-glutamyl-aspartic acid; T-31 peptide; AED.
Research-grade specifications: research suppliers of Cartalax 20mg (Bioregulator) list contents as 20 mg lyophilised Cartalax peptide per vial, with typical purity equal to or greater than 95–98% (exact figure varies slightly by supplier).
Excipient information for the Dermal Skin LTD Cartalax 20mg vial (e.g. bulking agents, stabilisers, buffer components) is not publicly listed.
Oral and lingual Cartalax bioregulator products from other manufacturers include excipients such as capsule shell materials and standard food-grade additives, but these compositions apply to their specific supplement formulations and not to the 20 mg lyophilised vial sold by Dermal Skin LTD.

Formulation

Form supplied by research vendors: lyophilised (freeze-dried) peptide powder, 20 mg Cartalax per vial, typically in a small glass vial.
AminoUSA and similar suppliers explicitly state contents as 20 mg lyophilised powder in a 3 mL vial with concentration ≥98% purity and requirement for reconstitution before use in laboratory research.
Dermal Skin LTD presents Cartalax 20mg (Bioregulator) with imagery consistent with a single vial presentation; the public product page does not specify whether the vial contains powder only or powder with any excipients, nor does it provide a detailed buffer or vehicle description.
Experimental dosage-protocol sources (not regulatory documents) suggest reconstitution of a 20 mg vial with 3.0 mL bacteriostatic water to yield approximately 6.67 mg/mL for research use; these instructions are explicitly framed as research guidance, not approved medical directions.
Separate Cartalax capsule and lingual products (from other brands) are formulated as oral and sublingual bioregulator supplements, but these dosage forms are distinct from the 20 mg research vial and are clearly labelled as non-medicinal products.
No official Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) or device Instructions for Use (IFU) exists for Cartalax as a licensed medicinal product in major regulatory territories.

Packaging

Cartalax 20mg (Bioregulator) on dermafillerltd.uk is shown as a small vial with a product label; detailed text on the label is not fully legible in the publicly accessible product image.
Research suppliers describe Cartalax 20mg as being supplied as a single 20 mg vial (lyophilised powder in a glass vial), often specified as a 3 mL vial as primary packaging.
Wholesale and manufacturing listings (e.g. chemical suppliers) describe bulk availability and show vials or small containers as packaging examples for Cartalax peptide, but do not provide detailed consumer-level packaging specifications.
Bioregulator capsule products (distinct from the vial) are sold in cartons containing blisters of capsules and clearly labelled with product name, batch number, expiry date and statements such as not a medicinal product; these details do not directly apply to the Dermal Skin LTD 20 mg vial.
No detailed information is publicly available on the carton artwork, tamper-evident features, or secondary packaging of the Dermal Skin LTD Cartalax 20mg vial beyond the website image.

Usage

Dermal Skin LTD’s public description focuses on benefits (supporting joint and cartilage health, enhancing mobility, aiding connective tissue recovery) and does not provide explicit instructions on dose, route of administration or course length for the Cartalax 20mg vial.
The product is marketed as suitable for individuals experiencing joint discomfort, athletes and ageing adults as part of broader musculoskeletal wellness, but concrete regimen details are not included on the visible product page.
Research suppliers of Cartalax 20mg consistently state that their peptide vials are intended strictly for laboratory research use and are not for human consumption, medical, veterinary or household use.
Independent peptide-dosage protocol sites provide example research reconstitution and administration schedules (e.g. reconstitution with bacteriostatic water and subcutaneous administration in research models), but these are explicitly described as non-clinical research guidance rather than approved medical directions.
Oral and lingual Cartalax bioregulator products from other brands (capsules or sublingual forms) typically recommend daily use over 1–3 months as a supplement course, but those instructions are specific to those non-medicinal products and are not official therapeutic guidance.
In the absence of regulator-approved labelling, any use of Cartalax 20mg outside laboratory research or clearly labelled supplement contexts would be off-label and unlicensed and must be assessed within appropriate ethical and legal frameworks.

Contraindications

Not a medical product

Adverse Effects

Not a medical product

Storage Conditions

Research suppliers for Cartalax 20mg recommend storing lyophilised peptide vials in a cool, dry place, typically refrigerated at 2–8 °C and protected from light to maintain stability.
Some protocol resources advise that lyophilised peptide may be stored at 2–8 °C or frozen at approximately −20 °C for longer-term storage, and that after reconstitution the solution should be refrigerated at 2–8 °C and used within a limited period, avoiding repeated freeze–thaw cycles.
Chemical-product listings state that Cartalax peptide should be kept in a tightly closed container in a cool, dry, well-ventilated area, away from direct sunlight.
Cartalax capsule and lingual products (separate commercial forms) are generally labelled for storage at room temperature in a dry place, away from direct sunlight and out of reach of children; these instructions apply specifically to those oral/sublingual forms.
The Dermal Skin LTD Cartalax 20mg (Bioregulator) product page does not separately specify storage conditions for the vial, so users rely on general peptide storage practices and any instructions provided with the delivered product.